




Supplementary Table 1 for Figure 1:

Cell line	Phenotype	GD2 expression	Remarks
NMB	Adrenergic	+++	
IMR-32	Adrenergic	+++	
LAN-1	Adrenergic	+++	
SHEP-2	Mesenchymal	+	Derived from SK-N-SH cells, isogenic pair with SH-SY5Y
SK-N-AS	Mesenchymal	±	
SH-SY5Y	Adrenergic	-	Derived from SK-N-SH cells, isogenic pair with SHEP-2
SK-N-BE	Adrenergic	-	
691B	Adrenergic	+++	Derived from patient 691, bone marrow metastasis (B)


Supplementary Figure 1:



Supplementary Figure 2 for **Figure 1**:

Supplementary Figure 3 for **Figure 1**:

Supplementary Figure 4 for Figure 4:



Supplementary Table 2 for Figure 5:

Patient	INRG stage*	Gender	Immunotherapy treatment cycle at time of blood sampling**
1	High-risk	Male	1
2	High-risk	Male	3, 5
3	High-risk	Female	5
4	High-risk	Male	1, 3
5	High-risk	Male	1
6	High-risk	Male	1

*INRG= International Neuroblastoma Risk Group

**During cycles 1, 3 and 5 GM-CSF was administered at a dose of 250 µg/m²/day for 3 days prior to blood sampling, and before the start of dinutuximab treatment. No samples were obtained during treatment cycles 2 and 4 where patients receive IL-2.

Supplementary Figure 5 for **Figure 5:**